438 related articles for article (PubMed ID: 17502350)
1. Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells.
Shi B; Liang J; Yang X; Wang Y; Zhao Y; Wu H; Sun L; Zhang Y; Chen Y; Li R; Zhang Y; Hong M; Shang Y
Mol Cell Biol; 2007 Jul; 27(14):5105-19. PubMed ID: 17502350
[TBL] [Abstract][Full Text] [Related]
2. EZH2-mediated concordant repression of Wnt antagonists promotes β-catenin-dependent hepatocarcinogenesis.
Cheng AS; Lau SS; Chen Y; Kondo Y; Li MS; Feng H; Ching AK; Cheung KF; Wong HK; Tong JH; Jin H; Choy KW; Yu J; To KF; Wong N; Huang TH; Sung JJ
Cancer Res; 2011 Jun; 71(11):4028-39. PubMed ID: 21512140
[TBL] [Abstract][Full Text] [Related]
3. EZH2 regulates the transcription of estrogen-responsive genes through association with REA, an estrogen receptor corepressor.
Hwang C; Giri VN; Wilkinson JC; Wright CW; Wilkinson AS; Cooney KA; Duckett CS
Breast Cancer Res Treat; 2008 Jan; 107(2):235-42. PubMed ID: 17453341
[TBL] [Abstract][Full Text] [Related]
4. MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes.
Fujii S; Tokita K; Wada N; Ito K; Yamauchi C; Ito Y; Ochiai A
Oncogene; 2011 Sep; 30(39):4118-28. PubMed ID: 21499305
[TBL] [Abstract][Full Text] [Related]
5. miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling.
Guo Y; Ying L; Tian Y; Yang P; Zhu Y; Wang Z; Qiu F; Lin J
FEBS J; 2013 Sep; 280(18):4531-8. PubMed ID: 23815091
[TBL] [Abstract][Full Text] [Related]
6. EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling.
Chang CJ; Yang JY; Xia W; Chen CT; Xie X; Chao CH; Woodward WA; Hsu JM; Hortobagyi GN; Hung MC
Cancer Cell; 2011 Jan; 19(1):86-100. PubMed ID: 21215703
[TBL] [Abstract][Full Text] [Related]
7. Context-specific regulation of NF-κB target gene expression by EZH2 in breast cancers.
Lee ST; Li Z; Wu Z; Aau M; Guan P; Karuturi RK; Liou YC; Yu Q
Mol Cell; 2011 Sep; 43(5):798-810. PubMed ID: 21884980
[TBL] [Abstract][Full Text] [Related]
8. The Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancer.
Zeidler M; Kleer CG
J Mol Histol; 2006 Sep; 37(5-7):219-23. PubMed ID: 16855786
[TBL] [Abstract][Full Text] [Related]
9. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
[TBL] [Abstract][Full Text] [Related]
10. Mastermind-like 1 Is a specific coactivator of beta-catenin transcription activation and is essential for colon carcinoma cell survival.
Alves-Guerra MC; Ronchini C; Capobianco AJ
Cancer Res; 2007 Sep; 67(18):8690-8. PubMed ID: 17875709
[TBL] [Abstract][Full Text] [Related]
11. Ezh2 reduces the ability of HDAC1-dependent pRb2/p130 transcriptional repression of cyclin A.
Tonini T; Bagella L; D'Andrilli G; Claudio PP; Giordano A
Oncogene; 2004 Jun; 23(28):4930-7. PubMed ID: 15077161
[TBL] [Abstract][Full Text] [Related]
12. Decreased expression of EZH2 is associated with upregulation of ER and favorable outcome to tamoxifen in advanced breast cancer.
Reijm EA; Jansen MP; Ruigrok-Ritstier K; van Staveren IL; Look MP; van Gelder ME; Sieuwerts AM; Sleijfer S; Foekens JA; Berns EM
Breast Cancer Res Treat; 2011 Jan; 125(2):387-94. PubMed ID: 20306127
[TBL] [Abstract][Full Text] [Related]
13. The Polycomb group protein EZH2 directly controls DNA methylation.
Viré E; Brenner C; Deplus R; Blanchon L; Fraga M; Didelot C; Morey L; Van Eynde A; Bernard D; Vanderwinden JM; Bollen M; Esteller M; Di Croce L; de Launoit Y; Fuks F
Nature; 2006 Feb; 439(7078):871-4. PubMed ID: 16357870
[TBL] [Abstract][Full Text] [Related]
14. Autocrine WNT signaling contributes to breast cancer cell proliferation via the canonical WNT pathway and EGFR transactivation.
Schlange T; Matsuda Y; Lienhard S; Huber A; Hynes NE
Breast Cancer Res; 2007; 9(5):R63. PubMed ID: 17897439
[TBL] [Abstract][Full Text] [Related]
15. EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells.
Kleer CG; Cao Q; Varambally S; Shen R; Ota I; Tomlins SA; Ghosh D; Sewalt RG; Otte AP; Hayes DF; Sabel MS; Livant D; Weiss SJ; Rubin MA; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11606-11. PubMed ID: 14500907
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of the polycomb group gene, EZH2, in transitional cell carcinoma of the bladder.
Raman JD; Mongan NP; Tickoo SK; Boorjian SA; Scherr DS; Gudas LJ
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8570-6. PubMed ID: 16361539
[TBL] [Abstract][Full Text] [Related]
17. Hsp90α Mediates BMI1 Expression in Breast Cancer Stem/Progenitor Cells through Facilitating Nuclear Translocation of c-Myc and EZH2.
Lee YC; Chang WW; Chen YY; Tsai YH; Chou YH; Tseng HC; Chen HL; Wu CC; Chang-Chien J; Lee HT; Yang HF; Wang BY
Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28914785
[TBL] [Abstract][Full Text] [Related]
18. A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells.
Poulsen TT; Pedersen N; Juel H; Poulsen HS
Cancer Gene Ther; 2008 Sep; 15(9):563-75. PubMed ID: 18421308
[TBL] [Abstract][Full Text] [Related]
19. Importance of Ezh2 polycomb protein in tumorigenesis process interfering with the pathway of growth suppressive key elements.
Tonini T; D'Andrilli G; Fucito A; Gaspa L; Bagella L
J Cell Physiol; 2008 Feb; 214(2):295-300. PubMed ID: 17786943
[TBL] [Abstract][Full Text] [Related]
20. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]